Immunotherapy with immune-checkpoint inhibitors and molecularly targeted therapy with BRAF inhibitors were pioneered in the setting of advanced-stage, unresectable melanoma, where they revolutionized treatment and considerably improved patient survival. These therapeutic approaches have also been successfully transitioned into the resectable disease setting, with the regulatory approvals of ipilimumab, pembrolizumab, nivolumab, and dabrafenib plus trametinib as postoperative (adjuvant) treatments for various, overlapping groups of patients with high-risk melanoma. Moreover, these agents have shown variable promise when used in the preoperative (neoadjuvant) period. The expanding range of treatment options available for resectable high-risk melanoma, all of which come with risks as well as benefits, raises questions over selection of the optimal therapeutic strategy and agents for each individual, also considering that many patients might be cured with surgery alone. Furthermore, the use of perioperative therapy has potentially important implications for the management of patients who have disease recurrence. In this Viewpoint, we asked four expert investigators and medical or surgical oncologists who have been involved in the key studies of perioperative systemic therapies for their perspectives on the optimal management of patients with high-risk melanoma.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gershenwald, C. A. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472–492 (2017).
Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 643–654 (2021).
Dummer, R. et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N. Engl. J. Med. 383, 1139–1148 (2020).
Luke, J. J. et al. LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Ann. Oncol. 32, S1283–S1346 (2021).
Luke, J. J. et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet, https://doi.org/10.1016/S0140-6736(22)00562-1 (2022).
Ascierto, P. A. et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 21, 1465–1477 (2020).
Zimmer, L. et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 395, 1558–1568 (2020).
Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301–309 (2021).
Tetzlaff, M. T. et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann. Oncol. 29, 1861–1868 (2018).
Rozeman, E. A. et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat. Med. 27, 256–263 (2021).
Amaria, R. N. et al. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. J. Clin. Oncol. 39, 9502 (2021).
Eggermont, A. M. M. et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur. J. Cancer 119, 1–10 (2019).
Eggermont, A. M. M. et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Eur. J. Cancer 158, 156–168 (2021).
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N. Engl. J. Med. 381, 626–636 (2019).
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239–1251 (2019).
Atkins, M. B. et al. DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): a phase III trial — ECOG-ACRIN EA6134. J. Clin. Oncol. 39, 356154 (2021).
Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
Kakavand, H. et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin. Cancer Res. 21, 3140–3148 (2015).
Grossmann, K. F. et al. Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-1141 (2021).
Livingstone, A. et al. Preferences for immunotherapy in melanoma: a systematic review. Ann. Surg. Oncol. 27, 571–584 (2020).
Livingstone, A. et al. Should I have adjuvant immunotherapy? An interview study among adults with resected stage 3 melanoma and their partners. Patient 14, 635–647 (2021).
Long, G. V. et al. Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). Cancer Res. 81, CT004 (2021).
Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655–1661 (2018).
Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948–960 (2019).
Blank, C. U. et al. First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J. Clin. Oncol. 38, 10002 (2020).
Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).
André, T. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): the GERCOR NEONIPIGA phase II study. J. Clin. Oncol. 40, 244 (2022).
Necchi, A. et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur. Urol. 77, 439–446 (2020).
Rouanne, M. et al. Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder. Eur. Urol. Oncol. 3, 728–738 (2020).
Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706–1714 (2020).
van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839–1844 (2020).
Vos, J. L. et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat. Commun. 12, 7348 (2021).
Maio, M. et al. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: the future is now! Eur. J. Cancer 152, 155–164 (2021).
Lipson, E. J. et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). J. Clin. Oncol. 39, 9503 (2021).
Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382–1399 (2016).
Regan, M. M. et al. Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition — a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 37, 3350–3358 (2019).
Dummer, R. et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 21, 358–372 (2020).
Newell, F. et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 40, 88–102 (2022).
Greenhaw, B. N. et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J. Am. Acad. Dermatol. 83, 745–753 (2020).
Tan, L. et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann. Oncol. 30, 804–814 (2019).
Long, G. V. et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 17, 1743–1754 (2016).
Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60–65 (2017).
Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 24, 4960–4967 (2018).
Hauschild, A. et al. Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600–mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials. JAMA Oncol. 4, 1382–1388 (2018).
Melanoma Institute Australia. Risk Prediction Tools, https://www.melanomarisk.org.au (2022).
Blank, C. U. et al. LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): the DONIMI study. Ann. Oncol. 32, S1283–S1346 (2021).
Zaremba, A. et al. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur. J. Cancer 155, 268–280 (2021).
Olson, D. J. et al. Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J. Clin. Oncol. 39, 2647–2655 (2021).
Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656–2666 (2021).
Owen, C. N. et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Ann. Oncol. 31, 1075–1082 (2020).
Bhave, P. et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. Br. J. Cancer 124, 574–580 (2021).
Eggermont, A. M. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
Eggermont, A. M. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).
Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).
Hauschild, A. et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAFV600-mutant stage III melanoma. J. Clin. Oncol. 36, 3441–3449 (2018).
Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).
Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789–1801 (2018).
Eggermont, A. M. M. et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: new results from the EORTC 1325-MG/KEYNOTE-054 trial. J. Clin. Oncol. 38, 3925–3936 (2020).
Long, G. V. et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 20, 961–971 (2019).
The work of G.V.L. is supported by an Australian National Health and Medical Research Council Investigator Grant and the University of Sydney Medical Foundation. J.J.L. acknowledges grant support from the US Department of Defense (W81XWH-17-1-0265), the NIH (UM1CA186690-06, P50CA254865-01A1 and P30CA047904-32), State of Pennsylvania Tobacco Phase 20 Formula Funds, as well as the UPMC Hillman Cancer Center via the Sy Holzer Endowed Immunotherapy Research Fund Award and as a Hillman Senior Faculty Fellow for Innovative Cancer Research.
A.M.M.E. has served on data safety monitoring boards for Biocad, BioNTech, GlaxoSmithKline (GSK), Novartis and Pfizer; and has served on scientific advisory boards for Agenus, Biocad, BioInvent, CatalYm, Clover, Ellipses, Galecto, GSK, IO Biotech, Merck, Nektar, Sairopa, Sellas, SkylineDx, TigaTx and TTxDiscovery. O.H. has received speaker’s bureau from Bristol Myers Squibb (BMS), Novartis, Pfizer and Sanofi/Regeneron; is a consultant for Aduro, Akeso, Alkermes, Amgen, Beigene, Bioatla, BMS, GSK, lmmunocore, ldera, lncyte, lnstilBio, lovance, Janssen, Merck, NextCure, Novartis, Pfizer, Roche/Genentech, Sanofi/Regeneron, Seattle Genetics, Tempus and Zelluna; and is at a contracted research institution for Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, GSK, lmmunocore, ldera, lncyte, lovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Roche/Genentech, Rubius, Sanofi/Regeneron, Seattle Genetics, Taiga, Torque and Zelluna. G.V.L. is a consultant/adviser for Agenus, Amgen, Array Biopharma, Boehringer Ingelheim, BMS, Evaxion Biotech, Hexal AG (Sandoz Company), Highlight Therapeutics, Merck Sharpe & Dohme, Novartis, OncoSec, Pierre Fabre, Provectus, Qbiotics and Regeneron. J.J.L. has served on data safety monitoring boards for Abbvie, Immutep and Evaxion. He has served on scientific advisory boards without equity consideration for 7 Hills, Bright Peak, Exo, Fstar, Inzen, RefleXion and Xilio, and with equity consideration for Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, Pyxis, Stipe and Tempest. He has held consultancy roles with compensation for Abbvie, Alnylam, Bayer, BMS, Castle, Checkmate, Codiak, Crown, Day One, Duke St, EMD Serono, Endeavor, Flame, Genentech, Gilead, HotSpot, Ikena, Immunocore, Incyte, Janssen, Kadmon, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Regeneron, Servier, STINGthera, Synlogic and Synthekine. He has received research support (all to his institution for clinical trials unless noted) from AbbVie, Astellas, AstraZeneca, BMS (for both investigator-initiated and industry trials), Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, NextCure, Numab, Palleon, Pfizer (investigator-initiated and industry trials), Replimmune, Rubius, Servier (investigator-initiated trials), Scholar Rock, Synlogic, Takeda, Tizona, Trishula and Xencor. He holds intellectual property on the following patents: Serial #15/612,657 (Cancer Immunotherapy); PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Eggermont, A.M.M., Hamid, O., Long, G.V. et al. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol 19, 431–439 (2022). https://doi.org/10.1038/s41571-022-00630-4